A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

Ajai Chari,Hearn Jay Cho,Samir Parekh, Amishi Dhadwal, Katarzyna Garcia,G. Morgan, Natalie Belostotsky, Crystle Carter,Donna Catamero,Juliet Escalon,Daniel Verina, Moon-hee Yum,Lisa La,Elaine Chan, Jude Gullie,Sundar Jagannath

Journal of Clinical Oncology（2015）

引用 0|浏览1

暂无评分

摘要

8528 Background: Preclinical data support deacetylation of oncogenic proteins/histones with the pan histone deacetylase inhibitor (HDACi) panobinostat (pan), which renders MM cells more susceptible...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要